SinoMab BioScience Limited — Regulatory Filings 2020

Jan 29, 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [29 x 44] intentionally omitted <==

==> picture [29 x 44] intentionally omitted <==

SinoMab BioScience Limited 中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3681)

VOLUNTARY ANNOUNCEMENT – UPDATE ON SN1011

Reference is made to the announcement of the Company dated 14 November 2019 (the “ Announcement ”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Announcement.

The Board wishes to provide a further update on the progress of the clinical trial of one of the Group’s key products, SN1011.

With regards to SN1011’s Phase I clinical trial in Australia, the Company has been carrying out the clinical trial studies in relation to the evaluation of the safety and tolerability of SN1011 in a group of healthy adult subjects in respect of both single ascending dose (the “ SAD ”) and multiple ascending doses. The Board is pleased to announce that as at 15 January 2020, the clinical trial in respect of SAD has been completed with 40 subjects participated in the clinical trial.

A single dose range of 25 to 200mg of SN1011 was generally safe and well tolerated by the subjects. A total of 17 adverse events were recorded, all of which were mild, and none of them were moderate or serious. Out of the 17 adverse events, (i) two adverse events (namely, nightmare and drowsiness) might be related to SN1011, (ii) three adverse events (namely, hiccup, headache and electrocardiography point stimulation) might be unrelated to SN1011, and (iii) 12 adverse events were unrelated to SN1011. All of the symptoms experienced by the subjects affected by the abovementioned adverse events have been relieved or recovered, and no significant dose-dependent relationship with SN1011 was found. The proportion of various types of adverse events are as follows: five cases (29%) relating to ECG operation, six cases (35%) relating to pain, and one case (6%) relating to each of nightmare, drowsiness, cough, hiccup, flatulence and edema on the back of the right hand. In respect of pharmacokinetic data, the preliminary analysis has shown that within the single dose range of 25 to 200 mg, the plasma Cmax (i.e. peak plasma concentration) of SN1011 increased linearly with the dose.

By order of the Board of Directors SinoMab BioScience Limited Dr. Shui On LEUNG Executive Director, Chairman and Chief Executive Officer

Hong Kong, 29 January 2020

As at the date of this announcement, the executive Directors are Dr. Shui On LEUNG and Mr. Jing QIANG, the non-executive Directors are Ms. Wenyi LIU, Dr. Haigang CHEN, Mr. Senlin LIU, Mr. Huiyuan MA and Mr. Xun DONG, and the independent non-executive Directors are Mr. Dylan Carlo TINKER, Mr. Michael James Connolly HOGAN, Mr. Ping Cho Terence HON and Mr. George William Hunter CAUTHERLEY.